ALBANY, N.Y. and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Curia, a
leading contract research, development and manufacturing organization and
Carterra Inc., the world leader in label-free high throughput antibody and small
molecule drug discovery, today announced their partnership in hosting a high-
throughput biologics symposium slated for May 31 at the Residence Inn at
Marriott in Seattle, Washington.
The purpose of the collaboration is to promote the rising biotech focus within
the Pacific Northwest region of the U.S and Canada. The symposium will bring
together all levels of scientific leadership from the biotech and pharma
communities.
"We are thrilled to be partnering with Carterra to organize this antibody
discovery symposium, bringing the Pacific Northwest biotech community together
and sharing the latest advances in antibody discovery," said Steve Lavezoli,
Vice President of Biologics at Curia. "We are also looking forward to sharing
our optimal, high-quality and accelerated antibody discovery workflows to first-
to-human antibody discovery, development and clinical manufacturing. Antibodies
discovered and/or engineered with Curia's platform technology are in the clinic
and we have over 230 successful antibody discovery campaigns performed for the
biotech community."
Speed, scientific expertise and efficiency can surmount the high attrition rates
of early antibody discovery and achieve first-to-market delivery of new
therapeutics. The symposium will highlight Curia's technology platform and
integrated services with a focus on the development of enhanced mouse systems
for antibody generation and high-throughput single B cell screening. The
combination of next generation sequencing (NGS) and rapid recombinant production
of milligram to gram quantities of purified monoclonal antibody (mAb)
significantly accelerates identification of development candidate leads.
Since 2017, Carterra has been selling its powerful LSA(®) high-throughput
biosensor to analyze and characterize antibodies using Surface Plasmon Resonance
(SPR). With the launch of its LSA(XT )platform last year, Carterra now offers
products that can perform small molecule analysis as well as antibody discovery.
The LSA platform has been profiled in several peer-reviewed papers in Science,
Nature and Cell, detailing the path of multiple therapeutics entering clinical
trials. At the symposium, several leading scientists in biopharma will be
sharing their insights into their specific areas of drug discovery and will
highlight the transformative impact of integrating HT-SPR technology, AI/ML and
other new technologies.
"We are excited to be partnering with Curia on our symposium. Carterra symposia
are scientific events that we host each year throughout the U.S. and Europe,"
stated Chris M. Silva, Vice President of Marketing and Product at Carterra.
"These symposia help us to share the latest technology advancements and
important data generated from the workflows of scientists using Carterra's
label-free platforms. Coming to the Pacific Northwest is an opportunity to
create a deeper understanding of the technology in pharma and biotechs in this
region."
Click here to RSVP for the event (https://info.carterra-bio.com/seattle-
symposium-2024). Registration is required as seating is limited.
About Curia:
Curia is a Contract Development and Manufacturing Organization (CDMO) with over
30 years of experience, an integrated network of 27 global sites and over 3,500
employees partnering with Biopharmaceutical customers to bring life-changing
therapies to market. Our biologics and small molecules offerings span discovery
through commercialization, with integrated regulatory and analytical
capabilities. Our scientific and process experts and state-of-the-art facilities
deliver best-in-class experience across drug substance and drug product
manufacturing. From curiosity to cure, we deliver every step to improve
patients' lives. Visit us at curiaglobal.com (https://curiaglobal.com/).
About Carterra, Inc.:
Carterra, Inc. is a privately held company. Its HT-SPR technology provides
large-molecule and small-molecule drug discovery customers with screening and
characterization throughput and functionality that scales with omics-level
applications, condensing months of work down to days. Our solutions have enabled
multiple therapeutics and breakthrough research and helped academic and
translational researchers and biopharmaceutical companies in oncology,
immunology, neuroscience, and more. Carterra is based in Salt Lake City, Utah,
and has Customer Experience Centers in San Francisco, Salt Lake
City, Boston, Manchester, England, and Munich, Germany. Carterra products are
available in Asia-Pacific and Oceania through our exclusive distributor,
Revvity. To learn more, visit www.carterra-bio.com
(https://c212.net/c/link/?t=0&l=en&o=4110584-
1&h=989151731&u=https%3A%2F%2Fnam12.safelinks.protection.outlook.com%2F%3Furl%3D
http%253A%252F%252Fwww.carterra-
bio.com%252F%26data%3D05%257C02%257C%257C55ae9d5e7ad54c6c1a1208dc330cb6eb%257C71
a51ab7f4a2416597c208ea50815deb%257C0%257C0%257C638441376892463292%257CUnknown%25
7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%25
3D%257C0%257C%257C%257C%26sdata%3D1t5WFIzFwwPEKhxQSKZNNEqjsLM%252BOZY1ivZVHHBGeV
E%253D%26reserved%3D0&a=www.carterra-bio.com) or connect with us on LinkedIn or
X (Twitter).
Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com
(mailto:corporatecommunications@CuriaGlobal.com)
Carterra Media Contact:
Cheri Salazar
(408) 594-9400
csalazar@carterra-bio.com (mailto:csalazar@carterra-bio.com)
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-
86f0-4f6c-96f2-0eaa01c82784
Â